Synthesis, biological evaluation and docking studies of new pyrrolo[2,3-d] pyrimidine derivatives as Src family-selective tyrosine kinase inhibitors

References

• Ingley E. Src family kinases: regulation of their activities, levels and identification of new pathways. Biochim Biophys Acta 2008;1784:56–65.
   PubMed Web of Science ®Google Scholar
• Parang K, Sun G. Recent advances in the discovery of Src kinase inhibitors. Expert Opin Ther Patents 2005;15:1183–1207.
   Web of Science ®Google Scholar
• Gupta S, El-Rayes BF. Small molecule tyrosine kinase inhibitors in pancreatic cancer. Biologics 2008;2:707–715.
   PubMedGoogle Scholar
• Chong YP, Ia KK, Mulhern TD, Cheng HC. Endogenous and synthetic inhibitors of the Src-family protein tyrosine kinases. Biochim Biophys Acta 2005;1754:210–220.
   PubMed Web of Science ®Google Scholar
• Sen B, Johnson FM. Regulation of SRC family kinases in human cancers. J Signal Transduct 2011;2011:865819.
   PubMedGoogle Scholar
• Cao X, You QD, Li ZY, Wang XJ, Lu XY, Liu XR et al. Recent progress of SRC family kinase inhibitors as anticancer agents. Mini Rev Med Chem 2008;8:1053–1063.
   PubMed Web of Science ®Google Scholar
• Roskoksi R. Src kinase regulation by phosphorylation and dephosphorylation. Biochem Biophysical Res Commun 2005;331:1–14.
   PubMed Web of Science ®Google Scholar
• Hu G, Place AT, Minshall RD. Regulation of endothelial permeability by Src kinase signaling: vascular leakage versus transcellular transport of drugs and macromolecules. Chem Biol Interact 2008;171:177–189.
   PubMed Web of Science ®Google Scholar
• Finn RS. Targeting Src in breast cancer. Ann Oncol 2008;19:1379–1386.
   PubMed Web of Science ®Google Scholar
• Edwards J. Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer. Expert Opin Investig Drugs 2010;19:605–614.
   PubMed Web of Science ®Google Scholar
• Rothschild SI, Gautschi O, Haura EB, Johnson FM. Src inhibitors in lung cancer: current status and future directions. Clin Lung Cancer 2010;11:238–242.
   PubMed Web of Science ®Google Scholar
• Sakamoto M, Takamura M, Ino Y, Miura A, Genda T, Hirohashi S. Involvement of c-Src in carcinoma cell motility and metastasis. Jpn J Cancer Res 2001;92:941–946.
   PubMedGoogle Scholar
• Sawyer TK. Cancer metastasis therapeutic targets and drug discovery: emerging small-molecule protein kinase inhibitors. Expert Opin Investig Drugs 2004;13:1–19.
   PubMed Web of Science ®Google Scholar
• Rucci N, Susa M, Teti A. Inhibition of protein kinase c-Src as a therapeutic approach for cancer and bone metastases. Anticancer Agents Med Chem 2008;8:342–349.
   PubMed Web of Science ®Google Scholar
• Saad F, Lipton A. SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer. Cancer Treat Rev 2010;36:177–184.
   PubMed Web of Science ®Google Scholar
• Martin MW, Machacek MR. Update on lymphocyte specific kinase inhibitors: a patent survey. Expert Opin Ther Pat 2010;20:1573–1593.
   PubMed Web of Science ®Google Scholar
• Smolinska MJ, Page TH, Urbaniak AM, Mutch BE, Horwood NJ. Hck tyrosine kinase regulates TLR4-induced TNF and IL-6 production via AP-1. J Immunol 2011;187:6043–6051.
   PubMed Web of Science ®Google Scholar
• Poincloux R, Al Saati T, Maridonneau-Parini I, Le Cabec V. The oncogenic activity of the Src family kinase Hck requires the cooperative action of the plasma membrane- and lysosome-associated isoforms. Eur J Cancer 2009;45:321–327.
   PubMed Web of Science ®Google Scholar
• Gleixner KV, Mayerhofer M, Cerny-Reiterer S, Hörmann G, Rix U, Bennett KL et al. KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib. Blood 2011;118:1885–1898.
   PubMed Web of Science ®Google Scholar
• Resh MD. Fyn, a Src family tyrosine kinase. Int J Biochem Cell Biol 1998;30:1159–1162.
   PubMed Web of Science ®Google Scholar
• Saito YD, Jensen AR, Salgia R, Posadas EM. Fyn: a novel molecular target in cancer. Cancer 2010;116:1629–1637.
   PubMed Web of Science ®Google Scholar
• Belsches-Jablonski AP, Demory ML, Parsons JT, Parsons SJ. The src pathway as a therapeutic strategy. Drug Discov. Today: Ther. Strate. 2005;2:313–321.
   Google Scholar
• Noble ME, Endicott JA, Johnson LN. Protein kinase inhibitors: insights into drug design from structure. Science 2004;303:1800–1805.
   PubMed Web of Science ®Google Scholar
• Ye G, Tiwari R, Parang K. Development of Src tyrosine kinase substrate binding site inhibitors. Curr Opin Investig Drugs 2008;9:605–613.
   PubMedGoogle Scholar
• Zhu X, Kim JL, Newcomb JR, Rose PE, Stover DR, Toledo LM et al. Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors. Structure 1999;7:651–661.
   PubMed Web of Science ®Google Scholar
• Nam JS, Ino Y, Sakamoto M, Hirohashi S. Src family kinase inhibitor PP2 restores the E-cadherin/catenin cell adhesion system in human cancer cells and reduces cancer metastasis. Clin Cancer Res 2002;8:2430–2436.
   PubMed Web of Science ®Google Scholar
• Meyn MA 3rd, Smithgall TE. Small molecule inhibitors of Lck: the search for specificity within a kinase family. Mini Rev Med Chem 2008;8:628–637.
   PubMed Web of Science ®Google Scholar
• Schenone S, Brullo C, Musumeci F, Biava M, Falchi F, Botta M. Fyn kinase in brain diseases and cancer: the search for inhibitors. Curr Med Chem 2011;18:2921–2942.
   PubMed Web of Science ®Google Scholar
• Recchia I, Rucci N, Festuccia C, Bologna M, MacKay AR, Migliaccio S et al. Pyrrolopyrimidine c-Src inhibitors reduce growth, adhesion, motility and invasion of prostate cancer cells in vitro. Eur J Cancer 2003;39:1927–1935.
   PubMed Web of Science ®Google Scholar
• Traxler P, Bold G, Buchdunger E, Caravatti G, Furet P, Manley P et al. Tyrosine kinase inhibitors: from rational design to clinical trials. Med Res Rev 2001;21:499–512.
   PubMed Web of Science ®Google Scholar
• Wilson MB, Schreiner SJ, Choi HJ, Kamens J, Smithgall TE. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis. Oncogene 2002;21:8075–8088.
   PubMed Web of Science ®Google Scholar
• Pene-Dumitrescu T, Peterson LF, Donato NJ, Smithgall TE. An inhibitor-resistant mutant of Hck protects CML cells against the antiproliferative and apoptotic effects of the broad-spectrum Src family kinase inhibitor A-419259. Oncogene 2008;27:7055–7069.
   PubMed Web of Science ®Google Scholar
• Gangjee A, Vidwans A, Elzein E, McGuire JJ, Queener SF, Kisliuk RL. Synthesis, antifolate, and antitumor activities of classical and nonclassical 2-amino-4-oxo-5-substituted-pyrrolo[2,3-d]pyrimidines. J Med Chem 2001;44:1993–2003.
   PubMed Web of Science ®Google Scholar
• Technical Bulletin. ProFluor Src-family kinase assay, Revised 6/09, Promega Corporation, USA.
   Google Scholar